AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has failed to improve overall survival (OS) in ...
“As a company driven by science and patient-centricity, AstraZeneca stands in full support of this ... He said he hoped that ...
Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...
On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers ...
We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are ...
We recently published a list of 10 Best Big-Name Stocks to Buy Right ... selling on individual US-listed stocks […] A Phase 3 ...
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
9don MSN
Common medicines used to treat conditions including heartburn, reflux, indigestion and stomach ulcers may be the subject of a ...
Drugmakers at the top of the list were Astellas ... 40% of the nods made the grade. AstraZeneca and Novartis had a pair of drugs that made the grade. AZ's winners were Imjudo for liver and ...
Health and Me on MSN5d
GST Slashed On Three Cancer Drug: Here's How It Will Affect PatientsThe recent GST cut on cancer drugs could mean significant cost reductions for cancer treatment in India. Read to know how it ...
In 2022, the global oncology market was valued at approximately $203.42 billion and is expected to reach over $470.61 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback